Vasopressin in chronic kidney disease: an elephant in the room?
Perico et al. report that a dual arginine vasopressin (AVP) V(2) and V(1a) receptor antagonist lowers blood pressure, proteinuria, and glomerulosclerosis in 5/6 nephrectomized rats, pointing to its potential value in the treatment of chronic kidney disease (CKD). AVP likely contributes to CKD progression by its effects on renal hemodynamics, blood pressure, and mesangial and/or epithelial cells, but the relative contributions of V(2) and V(1a) receptors and potential usefulness of V(2) and V(1a) receptor antagonists remain ill defined.
Torres
Vicente E
VE
Mayo Clinic College of Medicine, Rochester, MN 55905, USA. torres.vicente@mayo.edu
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin / Q000378:metabolism*; D001794:Blood Pressure; D002908:Chronic Disease; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D007674:Kidney Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D011507:Proteinuria / Q000188:drug therapy / Q000378:metabolism; D051381:Rats; D017483:Receptors, Vasopressin / Q000378:metabolism*; D012084:Renin-Angiotensin System; D015398:Signal Transduction; D013997:Time Factors; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D065092:Antidiuretic Hormone Receptor Antagonists; D006727:Hormone Antagonists; D017483:Receptors, Vasopressin; D001127:Arginine Vasopressin